Oncotype DX tumor gene expression profiling in stage II colon cancer

PLoS Currents

Volumn , Issue SEP, 2010, Pages

  Webber, Elizabeth M ^a   Lin, Jennifer S ^a   Whitlock, Evelyn P ^a  

^a CENTER FOR HEALTH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84857035378     PISSN: None     EISSN: 21573999     Source Type: Journal    
DOI: 10.1371/currents.RRN1177     Document Type: Article

References (12)

1. Clark-Langone KM, Wu JY, Sangli C, et al. Biomarker discovery for colon cancer using a 761 gene RT-PCR assay. BMC Genomics. 2007;8:279.
2. O'Connell MJ, Yothers G, Paik S, et al. Relationship between tumor gene expression and recurrence in patients with stage II/III colon cancer treated with surgery + 5-FU/LV in NSABP C-06: Consistency of results with two other independent studies. Presented at: American Society of Clinical Oncology 2008 Gastrointestinal Cancers Symposium; January 25-27, 2008; Orlando, FL. Abstract 301.
3. Lavery I, Hammel J, Cowens J, et al. Relationship between tumor gene expression and recurrence in an observational cohort of patients with stage II/III colon cancer treated with surgery only: Quantitative RT-PCR assay of 375 genes in fixed paraffin-embedded (FPE) tissue. Presented at: American Society of Clinical Oncology 2008 Gastrointestinal Cancers Symposium; January 25-27, 2008; Orlando, FL. Abstract 302.
4. O'Connell MJ, Lavery IC, Gray RG et al Comparison of molecular and pathologic features of stage II and stage III colon cancer in four large studies conducted for development of the 12-gene colon cancer recurrence score. American Society of Clinical Oncology gastrointestinal Cancers Symposium, 2010, Abstract 280.
5. Kerr D, Gray R, Quirke P, et al. A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: Selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study [abstract 4000]. J Clin Oncol. 2009;27(suppl):15s.
6. Genomic Health. [Press relsease] Genomic Health's Oncotype DX® Colon Cancer Test Predicts Individualized Recurrence Risk for Stage II Colon Cancer Patients. May 14, 2009. Available at: http://investor.genomichealth.com/releasedetail.cfm?ReleaseID=384226. Accessed: Jan. 21, 2010.
7. Oncotype DX® Colon Cancer Assay. Prognosis Overview. Dec. 10, 2009. Hayes, Inc. Accessed: Dec. 23, 2009.
8. American Cancer Society (ACS) [website]. What are the key statistics for colorectal cancer? Updated May 18, 2009. Available at: http://www.cancer.org/docroot/cri/content/cri_2_4_1x_what_are_the_key_statistics_for_colon_and_rectum_cancer.asp. Accessed: Jan. 21, 2010.
9. Figueredo A, Coombes ME, Mukherjee S. Adjuvant Therapy for completely resected Stage II Colon Cancer. Cochrane Database of Systematic Reviews 2008, Issue 3. Art. No.: CD005390. DOI: 10.1002/14651858.CD005390.pub2.
10. Rasul KI, Kerr DJ. QUASAR Results: The Prognostic Validity of a Colon Cancer Recurrence Score and the Role of Multigene Profiles in Determining Risk. Current Colorectal Cancer Reports. Published Online. 14 April 2010
11. Gray RG, Quirke P, Handley K et al. Correlation of number of nodes examined and the 12-gene colon cancer recurrence score with recurrence in stage II colon cancer patients from QUASAR. American Society of Clinical Oncology Gastrointestinal cancers Symposium, 2010, Abstract 331.
12. ASCO/NCCN quality measures: breast and colorectal cancers. Alexandria (VA): American Society of Clinical Oncology, National Comprehensive Cancer Network, Inc.; 2007 Apr. 5 p.